Brought to you by 
BMS & Karo develop drugs for obesity & high cholesterol
09 Dec 2015
Executive Summary
Bristol-Myers Squibb and Karo Bio will develop drugs for metabolic disorders such as hypercholesterolemia and obesity. BMS gets exclusive worldwide rights to compounds discovered; Karo Bio gets milestones and royalties. Karo could get up to $40mm.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BMS & Karo develop drugs for obesity & high cholesterol
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice